Interface (TILE) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
12 May, 2026Executive summary
Net sales reached $331 million in Q1 2026, up 11.3% year-over-year, with 6.8% currency-neutral growth, driven by broad-based momentum across all product categories and key market segments, especially Corporate Office and Healthcare.
Adjusted earnings per diluted share rose 64% to $0.41, and net income increased 81.6% to $23.6 million, reflecting strong operational execution and margin expansion.
Launched new products, including noravant rubber flooring and new carpet tile collections, expanding addressable markets and advancing sustainability initiatives with over 50% recycled or bio-based materials.
Raised full-year 2026 guidance based on robust backlog, operational efficiencies, and continued margin expansion.
Maintained industry-leading adjusted gross profit margins and a robust balance sheet.
Financial highlights
Q1 2026 net sales were $331 million, up 11.3% year-over-year; adjusted gross profit margin improved to 38.3%, up 55 basis points.
Adjusted EBITDA reached $46.8 million (14.1% of net sales), up 26.3%; adjusted operating income was $32.7 million, up 28.6%.
Adjusted net income was $23.9 million, up from $14.6 million; GAAP net income was $23.6 million, up from $13.0 million.
Adjusted EPS was $0.41, up 64% from $0.25; diluted EPS (GAAP) was $0.40, up from $0.22.
Cash provided by operating activities was $13.5 million, up from $11.7 million.
Outlook and guidance
Full-year 2026 net sales guidance raised to $1.45–$1.48 billion, with adjusted gross margin of 38.8–39.0%.
Q2 2026 net sales expected at $385–$395 million, with adjusted gross margin of ~39.9%.
Adjusted SG&A expenses for the year projected at 26.2–26.4% of net sales; adjusted effective tax rate at 26%.
Capital expenditures for 2026 expected at ~$60 million.
Liquidity and cash flows expected to be sufficient for foreseeable requirements.
Latest events from Interface
- Proxy covers director elections, say-on-pay, auditor ratification, and strong ESG focus.TILE
Proxy filing1 Apr 2026 - Votes include board elections, executive pay, and auditor ratification, with online voting options.TILE
Proxy filing1 Apr 2026 - Record sales, margin expansion, and strong healthcare/education growth set stage for 2026.TILE
Q4 202524 Feb 2026 - Q2 2024 net sales up 5.2%, margin expansion, and raised outlook on strong order growth.TILE
Q2 20242 Feb 2026 - Q3 2024 delivered 10.7% sales growth, margin expansion, and record net income and EPS.TILE
Q3 202417 Jan 2026 - 2024 saw 4.3% sales growth, margin expansion, and improved leverage, with a strong 2025 outlook.TILE
Q4 202423 Dec 2025 - Proxy covers director elections, say-on-pay, auditor change, and highlights ESG leadership.TILE
Proxy Filing1 Dec 2025 - Votes include board elections, executive pay, and auditor ratification, with online voting options.TILE
Proxy Filing1 Dec 2025 - Q1 sales up 2.6%, Americas strong, guidance raised despite margin and macro headwinds.TILE
Q1 202528 Nov 2025